PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia - 研发专利新闻

添加时间:2011-04-07 原文发表:2011-03-23 人气:2

Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, Co-administration of a...

查看所有的文章内容需要 VIP会员权限查看

点这里复制本页地址发送给您QQ/MSN上的好友

• POZEN files motion for Treximet patent l

• BDSI's BEMA drug delivery technology rec

• USPTO grants patent to HistoRx methods f

• GenSpera strengthens intellectual proper

• USPTO rejects Biotage's re-examination a

• HPK receives Reissue Patent for digital

• Global settlement agreement reached in T

• Argentum responds to recent decision in

• European Patent Office grants ProtAffin

• US District Court rules in favor of Wats

• NephRx receives new U.S. patent for NX00

• USPTO grants patent to ULURU's Altrazeal

• NephRx receives new U.S. patent for NX00

• ACT to be awarded broad patent protectio

• Colorcon announces specific details on i

• VARI, Gentel Biosciences receive U.S. Pa

• USPTO issues Notice of Allowance to Alph

• US District Court rules against Watson i

• U.S. District Court rules in favor of Wa

• Biotectix acquires Chameleon BioSurfaces

网站首页

行业信息

市场快讯

SFDA新闻精选

调研报告

研发动态

研发专利新闻

新闻公告

您的位置：网站名称 → 研发专利新闻 → 正文